Safety and efficacy of a freeze-dried trivalent antivenom for snakebites in the Brazilian Amazon: An open randomized controlled phase IIb clinical trial

Iran Mendonça-da-Silva, Antônio Magela Tavares, Jacqueline Sachett, José Felipe Sardinha, Lilian Zaparolli, Maria Fátima Gomes Santos, Marcus Lacerda and Wuelton Marcelo Monteiro

PLOS Neglected Tropical Diseases, 2017, vol. 11, issue 11, 1-21

Abstract: Background: In tropical areas, a major concern regarding snakebites treatment effectiveness relates to the failure in liquid antivenom (AV) distribution due to the lack of an adequate cold chain in remote areas. To minimize this problem, freeze-drying has been suggested to improve AV stability. Methods and findings: This study compares the safety and efficacy of a freeze-dried trivalent antivenom (FDTAV) and the standard liquid AV provided by the Brazilian Ministry of Health (SLAV) to treat Bothrops, Lachesis and Crotalus snakebites. This was a prospective, randomized, open, phase IIb trial, carried out from June 2005 to May 2008 in the Brazilian Amazon. Primary efficacy endpoints were the suppression of clinical manifestations and return of hemostasis and renal function markers to normal ranges within the first 24 hours of follow-up. Primary safety endpoint was the presence of early adverse reactions (EAR) in the first 24 hours after treatment. FDTAV thermal stability was determined by estimating AV potency over one year at 56°C. Of the patients recruited, 65 and 51 were assigned to FDTAV and SLAV groups, respectively. Only mild EARs were reported, and they were not different between groups. There were no differences in fibrinogen (p = 0.911) and clotting time (p = 0.982) recovery between FDTAV and SLAV treated groups for Bothrops snakebites. For Lachesis and Crotalus snakebites, coagulation parameters and creatine phosphokinase presented normal values 24 hours after AV therapy for both antivenoms. Conclusions/Significance: Since promising results were observed for efficacy, safety and thermal stability, our results indicate that FDTAV is suitable for a larger phase III trial. Trial registration: ISRCTNregistry: ISRCTN12845255; DOI: 10.1186/ISRCTN12845255 (http://www.isrctn.com/ISRCTN12845255). Author summary: Antivenoms (AV) are included in the WHO List of Essential Medicines, being the only treatment available for snakebites envenomings. In Brazil, five types of liquid snake AVs are distributed by the Ministry of Health for national use free of charge to patients. In remote areas, lack of an adequate cold chain impairs AV distribution to health facilities resulting in delay in patient care and, ultimately, in higher complication and case fatality rate. To minimize this problem, a freeze-drying process has been suggested to improve the stability of AVs, but freeze-dried AVs efficacy and safety evidence obtained from clinical trials is still very limited. Freeze-drying is a process by which water is removed from a sample without the need to apply heat. Benefits of lyophilization are: a) Samples are processed in aseptic conditions; b) Process does not use heat, ensuring formulation stability; c) Increases shelf life; d) Samples can be stored at room temperature for a long time; and e) Reduces weight and volume of samples, which is ideal for distribution. In this study, a freeze-dryed formulation is presented as a good alternative for a more stable trivalent antivenom in regions of the Amazon where high temperatures are common and the cold chain is poor. Our results suggest that such a product is adequate for a phase III trial.

Date: 2017
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006068 (text/html)
https://journals.plos.org/plosntds/article/file?id ... 06068&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pntd00:0006068

DOI: 10.1371/journal.pntd.0006068

Access Statistics for this article

More articles in PLOS Neglected Tropical Diseases from Public Library of Science
Bibliographic data for series maintained by plosntds ().